Abstract
Aldosterone, the key hormone in the mineralocorticoid pathway, plays a fundamental role in salt and water homeostasis, blood pressure regulation, and cardiovascular remodeling. Both genomic and nongenomic mechanisms influence aldosterone-induced renal sodium reabsorption. Furthermore, the mineralocorticoid receptors in nonepithelial tissues, including the heart and vascular smooth muscle cells, have recently been discovered. Thus, aldosterone likely has pleiotropic effects that contribute to the modulation of blood pressure. Among patients with hypertension in general, and among those with more severe or resistant hypertension in particular, a higher-than-expected prevalence of primary hyperaldosteronism is noted. Among individuals with resistant hypertension, aldosterone antagonists have also been shown to be effective in lowering blood pressure. Most significantly, recent community-based studies among non-hypertensive individuals in the general population have demonstrated that both higher serum aldosterone concentrations and a higher aldosterone to renin ratio portend a greater risk of developing hypertension. The combination of the aforementioned observations underscores the importance of the mineralocorticoid pathway in the pathogenesis of hypertension.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
• Milliez P, Girerd X, Plouin PF, et al. Emergence and evolution of the renin-angiotensin-aldosterone system. J Mol Med (Berl). 2012;90:495–508. This report presents a phylogenetic analysis of the evolution of the renin-angiotensin-aldosterone systems and notes that about 400 million years ago the pathway evolved in primitive chordates as the need for salt conservation and blood pressure maintenance arose.
Harris P. Evolution and the cardiac patient. Cardiovasc Res. 1983;17:437–45.
Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33–41.
• Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350:151–62. This report discusses the molecular mechanisms underlying the acute and chronic phases of aldosterone secretion in response to various physiological stimuli.
•• Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res. 2012;50:89–99. This is a comprehensive review of the multiple molecular mechanisms by which aldosterone impairs endothelial function.
•• Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514–23. This is a state-of-the-art review that discusses the pathogenesis of the two categories of mineralocorticoid-associated hypertension (with elevated and normal aldosterone levels) and disease mechanisms underlying this state.
Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary Aldosteronism. J Clin Endocrinol Metab. 2006;91:454–9.
Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci. 2003;100:14211–6.
Kathiresan S, Larson MG, Benjamin EJ, et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens. 2005;18:657–65.
Newton-Cheh C, Guo CY, Gona P, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension. 2007;49:846–56.
Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–8.
• Kisaka T, Ozono R, Ishida T, et al. Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension. J Hypertens. 2012;30:2322–30. Among Japanese patients with hypertension followed up for up to 9 years, those with higher ARR (above the median) had a 2.7-fold greater risk of stroke, and addition of ARR to the Framingham risk score increased model performance as evaluated by discrimination index (the C-statistic).
Stowasser M, Huggard PR, Rossetti TR, et al. Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial Hyperaldosteronism type I. J Clin Endocrinol Metab. 1999;84:4031–6.
Stowasser M, Bachmann AW, Huggard PR, et al. Severity of hypertension in familial Hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab. 2000;85:2160–6.
White PC. Inherited forms of mineralocorticoid hypertension. Hypertension. 1996;28:927–36.
•• Kaplan NM. Primary aldosteronism: evidence against a second epidemic. J Hypertens. 2012;30:1899–902. This review highlights the limitations of the ARR as a sole diagnostic tool for making a diagnosis of primary hyperaldosteronism and discusses how referral bias inflates prevalence estimates of the condition among hypertensive patients in different settings (primary care clinic vs. hypertension clinic vs resistant hypertension).
Jansen PM, Boomsma F, van den Meiracker AH. Aldosterone-to-renin ratio as a screening test for primary aldosteronism—the Dutch ARRAT Study. Neth J Med. 2008;66:220–8.
•• Clark III D, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012;28:318–25. This report highlights the high prevalence of primary hyperaldosteronism in patients with resistant hypertension, discusses the good response to spironolactone treatment in these patients and highlights the association of hyperaldosteronism with obstructive sleep apnea.
Kaplan NM. Cautions over the current epidemic of primary aldosteronism. Lancet. 2001;357:953–4.
•• Hannemann A, Bidlingmaier M, Friedrich N, et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol. 2012;167:7–15. This report elucidates how use of 3 different sets of diagnostic criteria (using a combination of high ARR, high serum aldosterone and reduced plasma renin concentrations) can result in widely varying prevalence estimates for primary hyperaldosteronism in hypertensive patients in the community.
Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary Aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266–81.
• Lieb W, Pencina MJ, Jacques PF, et al. Higher aldosterone and lower N-terminal proatrial natriuretic peptide as biomarkers of salt sensitivity in the community. Eur J Cardiovasc Prev Rehabil. 2011;18:664–73. This investigation demonstrates how the combination of higher salt intake, higher serum aldosterone and lower N-terminal proatrial natriuretic peptide concentrations can translate into a greater risk of developing hypertension prospectively among community-dwelling middle-aged adults.
•• Clark III D, Guichard JL, Calhoun DA, Ahmed MI. Recent advancements in the treatment of resistant hypertension. Postgrad Med. 2012;124:67–73. This review discusses the importance of aldosterone excess and responsiveness to spironolactone treatment in patients with resistant hypertension.
Acknowledgments
This work was supported in part by NIH/NHLBI contract N01-HC-25195 (R.S. Vasan).
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xanthakis, V., Vasan, R.S. Aldosterone and the Risk of Hypertension. Curr Hypertens Rep 15, 102–107 (2013). https://doi.org/10.1007/s11906-013-0330-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-013-0330-y